๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease

โœ Scribed by Vishal Bhagat; Ayse L. Mindikoglu; Carmine G. Nudo; Eugene R. Schiff; Andreas Tzakis; Arie Regev


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
218 KB
Volume
15
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

โœฆ Synopsis


Nonalcoholic steatohepatitis (NASH) is becoming a common cause of liver cirrhosis requiring liver transplantation (LT). Cardiovascular complications related to metabolic syndrome and NASH recurrence in the transplanted liver may affect the outcome of LT in these patients. We compared the outcomes of LT for NASH cirrhosis and alcoholic cirrhosis (ETOH) in a large transplant center. A retrospective chart review was performed for all patients who underwent LT for cryptogenic cirrhosis with the NASH phenotype (the NASH group) or ETOH (the ETOH group) at the University of Miami from January 1997 to January 2007. There was no significant difference in survival between the NASH and ETOH groups, despite a trend toward lower survival in the former (P = 0.1699). Sepsis was the leading cause of posttransplant death in both groups, and it was followed by cardiovascular causes in the NASH group (26% versus 7% in the ETOH group, P = 0.21) and malignancies in the ETOH group (29% versus 0% in the NASH group, P = 0.024). Recurrent steatohepatitis (33% versus 0%, P < 0.0001) and acute rejection (41% versus 23%, P < 0.023) were significantly more frequent in the NASH group than in the ETOH group. There was no difference in graft failure between the groups (24% in the NASH group versus 18% in the ETOH group, P = 0.3973). In conclusion, despite a numerical trend favoring the ETOH group, there were no statistically significant differences in posttransplant survival and cardiovascular mortality between the NASH and ETOH groups. Acute rejection and recurrent steatohepatitis were significantly more frequent in the NASH group but did not lead to higher rates of retransplantation.


๐Ÿ“œ SIMILAR VOLUMES


Outcomes of liver transplantation in pat
โœ Shahid M. Malik; Jawad Ahmad ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 38 KB ๐Ÿ‘ 1 views

We read with interest the article by Bhagat et al. 1 regarding outcomes of liver transplantation (LT) in patient with cirrhosis due to nonalcoholic steatohepatitis (NASH) versus patients with cirrhosis due to alcoholic liver disease. This retrospective study showed no statistical differences in post

Decreased muscle strength in patients wi
โœ Henning Andersen; Mette Borre; Johannes Jakobsen; Per Heden Andersen; Hendrik Vi ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 103 KB ๐Ÿ‘ 2 views

To study motor function quantitatively in alcoholic liver cirrhosis muscle strength, liver function, peripheral nerve function, and nutrition were assessed in 24 patients. Isokinetic strength of flexion and extension at elbow, wrist, hip, knee, and ankle and of shoulder abduction and adduction was e

Urinary sodium balance in patients with
โœ G Wensing; E Lotterer; I Link; E G Hahn; W E Fleig ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 178 KB ๐Ÿ‘ 1 views

The relationship between the impairment in hepatic and renal function in cirrhosis has not been well established. This study investigated urinary sodium excretion in comparison with quantitative parameters of liver function in 75 patients with various degrees of cirrhosis kept on a constant salt die

Effect of pretransplantation ursodeoxych
โœ Heathcote, E. Jenny ;Stone, Julie ;Cauch-Dudek, Karen ;Poupon, Raoul ;Chazouille ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 42 KB

As ursodeoxycholic acid (UDCA) delays the need for transplantation, this could result in patients with more comorbid disease, therefore more likely to have a worse outcome posttransplantation. The aim of this study is to compare posttransplantation outcome in patients who received UDCA versus placeb

Does antimitochondrial antibody status a
โœ W R Kim; J J Poterucha; R A Jorgensen; K P Batts; H A Homburger; E R Dickson; R ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 270 KB ๐Ÿ‘ 1 views

rum. 1 In the past decade, two treatment modalities have Approximately 5% to 10% of patients with features otherbeen shown to be effective in the treatment for PBC, dewise consistent with primary biliary cirrhosis (PBC) lack antipending on the stage of the disease. For patients with less mitochondri